The cheapest GLP-1 medication in the United States right now is generic liraglutide, approved by the FDA in December 2024 as the first generic version of Victoza. For brand-name options, the lowest out-of-pocket cost depends heavily on your insurance status, but several paths can bring monthly costs well below list price. Here’s how the options compare and what you can realistically expect to pay.
Brand-Name List Prices at a Glance
Before discounts, coupons, or insurance, GLP-1 medications carry steep monthly price tags. Ozempic lists at roughly $1,000 per month, Wegovy at about $1,350, and Zepbound at approximately $1,086. Rybelsus, the oral tablet form of the same active ingredient in Ozempic, lists at around $1,012 for a 30-day supply of the lowest dose. None of these brand-name drugs have approved generics yet (with one exception covered below), so these prices set the baseline for what pharmacies charge without negotiated discounts.
For context, those same medications cost a fraction of the price outside the U.S. A month of Ozempic lists at about $147 in Canada compared to $936 in the U.S. Rybelsus runs roughly $158 in Canada. The American list prices don’t reflect what most insured patients pay, but they’re what you’d face at the pharmacy counter without coverage.
Generic Liraglutide: The First Budget Option
The FDA approved the first generic GLP-1 in December 2024: a generic version of Victoza (liraglutide), made by Hikma Pharmaceuticals. It’s a once-daily injection approved for type 2 diabetes in adults and children 10 and older. This is the only GLP-1 with a generic equivalent on the U.S. market, which makes it the cheapest option at the pharmacy level for people paying out of pocket.
There’s an important limitation. Generic liraglutide is approved only for blood sugar control in type 2 diabetes, not for weight loss. If you’re looking specifically for an affordable GLP-1 for weight management and don’t have diabetes, this generic won’t be prescribed for that purpose. Liraglutide also produces more modest weight loss than newer GLP-1s like semaglutide or tirzepatide, so even for people with diabetes who want both benefits, it’s a trade-off between cost and effectiveness.
How to Lower Brand-Name Costs
If you need a brand-name GLP-1, the sticker price is rarely what you’ll actually pay. Manufacturer savings programs and recent pricing agreements have created several tiers of cost depending on your situation.
With Commercial Insurance
Novo Nordisk offers a Wegovy Savings Offer that can bring your copay down to as little as $25 per month if your commercial insurance covers the drug. The savings cap out at $100 off a one-month fill, $200 off a two-month fill, or $300 off a three-month supply. Eli Lilly runs a similar program for Zepbound. These programs don’t work with Medicare, Medicaid, or government insurance.
Without Insurance or Without Coverage
If you’re uninsured, have insurance that doesn’t cover GLP-1s, or choose to pay cash, the picture has improved. Novo Nordisk introduced introductory pricing on Wegovy: the oral tablet costs $149 per month for the 1.5 mg dose, and the injection pen starts at $199 per month for the lowest dose through the company’s savings offer. These prices climb with higher doses, but they represent a dramatic drop from the $1,349 list price.
A broader pricing shift is also underway. Under a negotiated agreement announced through the federal TrumpRx program, Ozempic and Wegovy are set to be available at $350 per month, down from $1,000 and $1,350. Zepbound would drop to an average of $346. If an oral version of Wegovy receives FDA approval, its introductory price through the program would be $150 per month. These prices apply to purchases made through the specific program, not necessarily at every pharmacy.
Medicare Coverage for GLP-1s
Medicare has historically not covered GLP-1 medications prescribed purely for weight loss. That’s changing, but slowly. A new program called the Medicare GLP-1 Bridge will run from July 2026 through December 2027, giving eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight reduction outside the normal Part D benefit structure.
Eligibility requires a prior authorization from your provider and meeting specific criteria. You’ll need a BMI of 35 or higher, or a BMI of 30 or higher with certain conditions like heart failure, uncontrolled high blood pressure, or chronic kidney disease (stage 3a or above). At a BMI of 27 or higher, you can qualify if you have pre-diabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease. The eligible drugs currently include Wegovy (both injection and tablets), Zepbound, and Foundayo.
If your GLP-1 is prescribed for diabetes rather than weight loss, it may already be covered under your Part D plan through standard formulary channels. The Bridge program specifically targets the weight-loss indication that Part D traditionally excludes.
Cheapest Per Pound Lost
Raw monthly cost doesn’t tell the whole story if your goal is weight loss. In a head-to-head clinical trial, Zepbound produced 20.2% average body weight loss over 72 weeks compared to 13.7% with Wegovy. That translates to roughly 50 pounds lost on Zepbound versus 33 pounds on Wegovy for the average participant. Nearly half of Zepbound users (48.4%) lost 20% or more of their body weight, compared to about 27% of Wegovy users.
At similar list prices (Zepbound at $1,086 versus Wegovy at $1,350 per month), Zepbound delivers significantly more weight loss per dollar. Over an 18-month treatment course at list price, you’d spend roughly $19,548 on Zepbound to lose an average of 50 pounds, or about $391 per pound. Wegovy over the same period would cost approximately $24,300 for 33 pounds lost, or about $736 per pound. If both drugs land near $350 per month through negotiated pricing, Zepbound’s efficiency advantage becomes even more pronounced: around $126 per pound lost versus $191.
Comparing Your Realistic Options
- Generic liraglutide: Lowest pharmacy cost, but only approved for type 2 diabetes. More modest weight and blood sugar effects than newer drugs.
- Wegovy (introductory pricing): $149 to $199 per month at lowest doses through the manufacturer savings offer for cash-pay patients. Higher doses cost more.
- Ozempic or Wegovy (negotiated pricing): $350 per month through the TrumpRx program when available.
- Zepbound (negotiated pricing): Approximately $346 per month through the same program, with greater average weight loss than Wegovy.
- With commercial insurance and manufacturer coupons: Potentially as low as $25 per month for Wegovy if your plan covers it.
The absolute cheapest GLP-1 is generic liraglutide for people with type 2 diabetes. For weight loss specifically, the lowest realistic cost is $25 per month with the right insurance and a manufacturer coupon, or $149 per month for Wegovy’s oral tablet at the introductory dose without insurance. Your actual price depends on which drug you need, what your insurance covers, and which savings programs you’re eligible for.